As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.
Citations
Citations to this article as recorded by
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial” Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Dynamics and Sensitivity of the Lifecycle of Hepatitis B Virus Dmitry Grebennikov, Igor Sazonov, Rostislav Savinkov, Matvey Zakharov, Mark Sorokin, Yakov Mokin, Andreas Meyerhans, Gennady Bocharov Pathogens.2026; 15(2): 172. CrossRef
ZNF638 represses the transcription of HBV closed circular DNA involving HUSH complex-mediated histone modifications of epigenetic silencing Sifan Meng, Jiaqian Li, Yunlong Fang, Binwei Duan, Jing Wang, Yang Si, Feng Li, Qiong Wu, Shan Cheng, Wei Ding Cell Communication and Signaling.2026;[Epub] CrossRef
Response to letters to editor "Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial" and “Critical Appraisal of the Anchor RCT on Entecavir, Peginterferon Alfa-2b, and GM-CSF Combination Therapy” Di Wu, Da Huang, Weiming Yan, Qin Ning Hepatology International.2026;[Epub] CrossRef
Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon Jianxia Dong, Sujun Zheng, Xinyue Chen Hepatology International.2026;[Epub] CrossRef
Mechanisms and management of pegylated interferon-α toxicity in chronic hepatitis B Liya Zhu, Fei Peng, Dingfang Pi, Jinzhi Lu Frontiers in Immunology.2026;[Epub] CrossRef
Long-term antiviral therapy sustains HBsAg decline, increases HBV RNA negativity and enhances the proportion of patients achieving functional cure in chronic hepatitis B Ruihan Gao, Shuting Liu, Shiyu Zhang, Xin Zhou, Bin Zhu, Baoju Wang Annals of Hepatology.2026; 31(2): 102212. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks Kui Wang, Ruchen Zhou Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
A Comparative Study of Entecavir and Tenofovir Alafenamide on Quantitative HBsAg Reduction in Patients With CHB Jungnam Lee, Young‐Joo Jin Journal of Medical Virology.2026;[Epub] CrossRef
Hepatitis B in Children: A Review of Current Knowledge and Future Directions Paola Carolina Espin Diaz, Swati Antala Current Treatment Options in Pediatrics.2026;[Epub] CrossRef
Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang iLIVER.2026; 5(2): 100235. CrossRef
Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controll Qiran Zhang, Feng Sun, Shulan Sui, Jianmei Lin, Chuncheng Wu, Jing Yuan, Yingli He, Jia Shang, Tao Han, Ying Zhu, Zuxiong Huang, Chen Chen, Chao Qiu, Xing Wang, Jiming Zhang, Yao Xie, Wenhong Zhang Advances in Therapy.2026; 43(8): 3660. CrossRef
Case Report: Probable manic episode induced by PEG-IFN α-2b in a chronic hepatitis B patient—multidisciplinary management insights Xiao-Cui Wu, Hui Zhou, Lan-Tian Pang, Cui-Lan Tang Frontiers in Medicine.2026;[Epub] CrossRef
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update Hong You, Rakhi Maiwall, Jing Chen, Sang Hoon Ahn, Kadir Dokmeci, Xiaoguang Dou, Manal El-Sayed, Jian-Gao Fan, Rino Gani, Zhiliang Gao, Jacob George, Hasmik Ghazinian, George Goh, Saeed Hamid, Jinlin Hou, Shang-Chin Huang, Dong Ji, Jidong Jia, Tatsuo Kand Hepatology International.2026;[Epub] CrossRef
PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B Mei Li, Dandan Feng, Juanjuan Shi, Shuangsuo Dang, Xiaoli Jia, Wenjun Wang Frontiers in Immunology.2026;[Epub] CrossRef
Comment on the expert consensus on treatment approaches for achieving functional cure in chronic hepatitis B: Letter to the editor on “Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0” Seng-Gee Lim, Melanie Paff Clinical and Molecular Hepatology.2026; 32(3): e285. CrossRef
Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction Kwon Yong Tak, Seok Hwan Kim, Myeong Jun Song The Korean Journal of Internal Medicine.2026; 41(4): 636. CrossRef
Optimizing pegylated interferon α‐2b consolidation duration and developing a recurrence prediction model after functional cure based on updated definition in chronic hepatitis B Yuchen Peng, Liping Liu, Xiaoping Wu European Journal of Medical Research.2026;[Epub] CrossRef
Advances in Viral Markers for Predicting Functional Cure of Chronic Hepatitis B Xinrong Lu, Xin Yang, Qishui Ou, Zhen Xun Portal Hypertension & Cirrhosis.2026;[Epub] CrossRef
Noninvasive models for patient selection and Early response monitoring of interferon therapy for HBsAg clearance in patients with chronic hepatitis B Zhaopei Guo, Yan Pan, Lin Lin, Xiangjun Tang, Weiquan You, Fengling Fang, Hongyan Guo, Yiming Zhong, Dina Haishaer, Lu Lai, Yue Shi, Yutong Li, Dong Huang, Kaixin Chen, Yongjie Xu, Ni Lin, Tianbin Chen, Yongbin Zeng, Qishui Ou, Ya Fu BMC Infectious Diseases.2026;[Epub] CrossRef
Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection Yiwen Shu, Sumeng Li, Yanqin Du, Xin Zheng Frontiers in Immunology.2025;[Epub] CrossRef
Quantitatively Evaluate the Improvement of Functional Cure for the Quality of Life of Chronic Hepatitis B Cases: Evidence from a Cross-Sectional Study in China Sihui Zhang, Zhiliang Gao, Hui Li, Yi Kang, Lei Fu, Xuebing Chen, Xiaoyuan Xu, Xinyue Chen, Hui Zhuang, Hui Zheng, Fuqiang Cui Healthcare.2025; 13(20): 2590. CrossRef
Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen Journal of Virus Eradication.2025; 11(4): 100617. CrossRef
An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection Ze-Ao Huang, Yang Yang, Shuo Yang, Guang-Shen Ji, Rui Fu, Zhi-Kang Tian, Yu-Cheng Wu, Geng-Shen Song Nature Communications.2025;[Epub] CrossRef
A Study on Serum Protein Tracking in Patients with Low Levels of HBsAg Undergoing Treatment for Chronic Hepatitis B with a Combination of Tenofovir Disoproxil Fumarate and Pegylated Interferon Yimin Chen, Min Deng, Mingkai Tong, Peixia Lin, Hua Xuan, Dahai Wei Hepatitis Monthly.2025;[Epub] CrossRef
Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study Jianxia Dong, Shan Ren, Jing Zhao, Pengxuan Wu, Haitian Yu, Yao Xie, Junliang Fu, Xiaorong Mao, Zhiliang Gao, Bingliang Lin, Qingfa Ruan, Yongfang Jiang, Xiulan Xue, Yueyong Zhu, Haidong Zhao, Haifang Cao, Xinyue Chen, Sujun Zheng Virology Journal.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao Hepatoma Research.2025;[Epub] CrossRef
First
Prev
